Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00086671 | Safety and Effectiveness of Two Doses of ABT-874 as Compared to Placebo in Subjects With Multiple Sclerosis (MS) | PHASE2 | COMPLETED | 215 | — | — | Apr 1, 2004 | Nov 1, 2006 | Jan 4, 2013 | 44 | United States, Canada +3 |
| Arm | Type | Description |
|---|---|---|
| ABT-874 200 mg weekly | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| ABT 874 QOW | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ABT-874/Human monoclonal antibody against IL-12 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Age between 18 and 55 years * Diagnosis of active relapse within 12 months of screening. * At least one relapse within 12 months of screening. * Must be able to walk at least 65 feet with or without assistance * Off Copaxone or interferon therapy for two months prior to screen...